Cargando…

Immunization of C57BL/6 Mice with GRA2 Combined with MPL Conferred Partial Immune Protection against Toxoplasma gondii

BACKGROUND: We have previously reported that immunization with GRA2 antigen of Toxoplasma gondii induces protective immunity in CBA/J (H2k) and BALB/c mice (H2d). We aimed to examine whether immunization of a distinct strain of rodent with recombinant dense granule antigens (GRA2) combined with mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Babaie, Jalal, Amiri, Samira, Homayoun, Robab, Azimi, Ebrahim, Mohabati, Reyhaneh, Berizi, Mahboobe, Sadaie, M. Reza, Golkar, Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712381/
https://www.ncbi.nlm.nih.gov/pubmed/28646827
http://dx.doi.org/10.22034/ibj.22.1.22
Descripción
Sumario:BACKGROUND: We have previously reported that immunization with GRA2 antigen of Toxoplasma gondii induces protective immunity in CBA/J (H2k) and BALB/c mice (H2d). We aimed to examine whether immunization of a distinct strain of rodent with recombinant dense granule antigens (GRA2) combined with monophosphorryl lipid A (MPL) adjuvant elicits protective immune response against T. gondii. METHODS: C57BL/6 (H2b haplotype) mice were immunized with GRA2, formulated in MPL adjuvant. RESULTS: Strong humoral response, predominantly of IgG1 subclass and cellular response, IFN-γ, was detected at three weeks post immunization. Mice immunized with GRA2 had significantly (p < 0.01) fewer brain cysts than those in the adjuvant group, upon challenge infection. Despite the production of a strong antibody response, IFN-γ production and brain cyst reduction were not significant when the immunized mice were infected four months after the immunization. CONCLUSIONS: We can conclude that GRA2 immunization partially protects against T. gondii infection in C57BL/6 mice, though the potency and longevity of this antigen as a standalone vaccine may vary in distinct genetic backgrounds. This observation further emphasizes the utility of GRA2 for incorporation into a multi-antigenic vaccine against T. gondii.